Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (now AIM ImmunoTech Inc.) on August 22, 2019. The filing documents a corporate name change and a corresponding change in the company's stock ticker symbol.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Corporate Name: The company changed its name from Hemispherx Biopharma, Inc. to AIM ImmunoTech Inc.
- Effective Date: The name change is effective September 3, 2019.
- Stock Ticker: The trading symbol on the NYSE American will change from "HEB" to "AIM" effective September 3, 2019.
- Legal Action: An amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on August 22, 2019.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors related to operations. The primary event is the rebranding of the entity.
Key Facts for Investor Verification
- Verify the new ticker symbol "AIM" on the NYSE American starting September 3, 2019.
- Confirm the legal name change to AIM ImmunoTech Inc. in corporate registries.
- Note that the filing includes a press release dated August 23, 2019, as Exhibit 99.1.